D3 Bio (德昇济医药)
Shanghai precision-oncology company led by a former AstraZeneca China R&D head, taking its KRAS G12C inhibitor into global Phase 3 on equity alone.
1. Core Product / Service
D3 Bio develops precision therapies for cancer and immune diseases [3]. Its lead asset is elisrasib (D3S-001), a next-generation oral KRAS G12C inhibitor. The December 2025 Series B was raised mainly to fund a global Phase 3 pivotal program. The program would test it alone and in combinations across the US, China and the EU [2]. Secondary reports say it holds FDA Breakthrough Therapy designation in pretreated KRAS G12C NSCLC and Orphan Drug designation in colorectal cancer; these were not verified against primary sources [1]. Other targeted and immuno-oncology programs have not been named [2].
2. Target Users & Pain Points
Patients with KRAS G12C-mutant lung, colorectal and other cancers. First-generation G12C inhibitors have limited depth and durability of response, and D3 positions elisrasib as a second-generation molecule. The company aims to file globally itself rather than license out early [2].
3. Competitive Landscape
| Player | Positioning | Vs. D3 Bio |
|---|---|---|
| Approved first-generation KRAS G12C inhibitors | Marketed in NSCLC and CRC | Incumbents elisrasib must beat on efficacy |
| Chinese KRAS G12C developers | Several domestic programs at or near approval | Crowded domestic field |
| scibrunch | Startup founded in 2024; licensed its KRAS G12D (ON) inhibitor to Merck | Different allele; sold early rather than self-developing |
| minghui-pharmaceutical | Also funds late-stage trials with equity | Similar "equity to Phase 3" path, different modality |
4. Unique Observations
- Equity-funded to Phase 3: D3 has raised about US$370M with no disclosed out-licensing deal [1]. ADC and siRNA peers founded at the same time (dualitybio, argo-biopharmaceutical) funded themselves largely through licensing.
- "Clinical-first" discovery: the company says it starts from unmet clinical need and works back to targets. Its name reflects a loop in which development informs discovery [5].
- Wet-lab model (unknown): there is no public information on labs, headcount or CRO use. The registered operating entity is in Wuxi, and WuXi AppTec's corporate venture fund has been an investor since the Series A [1][2]. Any reliance on the WuXi ecosystem for chemistry or CMC is an inference only.
5. Financials / Funding
| Round | Date | Amount | Investors |
|---|---|---|---|
| Series A | 2020-11 | US$200M | WuXi AppTec CVF, Temasek, Boyu Capital, Sequoia China (now HongShan/HSG), Matrix China and others [3][5] |
| Series A+ | 2024-04-08 | US$62M | Medicxi led; Matrix followed [4] |
| Series B | 2025-12-09 | US$108M | IDG Capital and SongQing Capital (new); WuXi AppTec CVF, Temasek, HSG, MPCi and Medicxi (existing) [2] |
- Total disclosed: about US$370M [1].
- One recruitment-site record attributes a "May 2026 US$108M strategic round" to D3. The record actually belongs to a different company and is excluded [1].
6. People & Relationships
- Co-founder, Chairman & CEO: 陈之键 (George Chen), an oncologist. He was formerly head of AstraZeneca's China R&D, with earlier roles at NIH, Eli Lilly, GSK, J&J and BeiGene [3][5].
- Founded: August 2020 [4].
- Peers: minghui-pharmaceutical, full-life-technologies.